Koselugo (selumetinib) for the Treatment of Neurofibromatosis Type 1 (NF1)
Koselugo (selumetinib) is mainly used for treating NF1 in paediatric patients whose age is two years and older. Credit: Astrazeneca.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more